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Abstract
Objective The objective of this study was to evaluate the
long-term efficacy of adding fenofibric acid to moderate-
dose statin therapy in patients at goal for low-density
lipoprotein cholesterol (LDL-C) but with persistent hyper-
triglyceridemia.
Methods This is a post hoc analysis of a subset of patients
(N=92) with mixed dyslipidemia treated with moderate-
dose statin (rosuvastatin 20 mg, simvastatin 40 mg, or
atorvastatin 40 mg) for 12 weeks in three controlled trials
who had achieved LDL-C <100 mg/dL but whose
triglycerides remained >200 mg/dL, and had fenofibric
acid 135 mg added to the moderate-dose statin in a 52-week
open-label extension study. Lipid and apolipoprotein (Apo)
values and the proportion of patients meeting individual
and combined treatment targets with combination therapy
were determined at scheduled visits during the 52-week
study and compared with baseline (start of extension
study).
Results Addition of fenofibric acid to moderate-dose statin
for 52 weeks resulted in significant (P<0.001) improve-
ments in non–high-density lipoprotein cholesterol (non–
HDL-C; –9.0%), ApoB (–9.8%), HDL-C (14.9%), and
triglycerides (–37.6%) compared with baseline. At final
visit, greater proportions of patients achieved optimal levels
of individual parameters as well as combined targets of
LDL-C+non–HDL-C (60.0% vs 52.2%), LDL-C+non–
HDL-C+ApoB (53.3% vs 37.8%, P=0.007), and LDL-C
+non–HDL-C+ApoB+HDL-C+triglycerides (25.6% vs
0.0%) than at baseline.
Conclusions The addition of fenofibric acid to moderate-dose
statin in patients whose LDL-C was optimal but whose
triglycerides remained >200 mg/dL led to additional improve-
ments in non–HDL-C, ApoB, HDL-C, and triglycerides that
resulted in greater proportions of patients attaining optimal
levels of the individual parameters as well as simultaneously
achieving optimal levels of these parameters and LDL-C.
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Introduction
Mixed dyslipidemia, characterized by elevated levels of
triglycerides (TG), low levels of high-density lipoprotein
cholesterol (HDL-C), elevated low-density lipoprotein
cholesterol (LDL-C), and a preponderance of small dense
particles is associated with additional coronary heart
disease (CHD) risk, compared with elevated LDL-C alone
[1–4]. National Cholesterol Education Program (NCEP)
Adult Treatment Panel (ATP) III identifies both elevated
TG and low levels of HDL-C as markers of increased
cardiovascular risk given that each is independently
associated with CHD risk [5]. Although LDL-C remains
the primary therapeutic target in the management of
dyslipidemia, NCEP ATP III also recommends non–HDL-
C as a secondary target of treatment in patients at LDL-C
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DOI 10.1007/s10557-011-6280-1goal with persistent hypertriglyceridemia (TG ≥200 mg/dL).
As an alternative to intensifying LDL-C–lowering therapy or
if tolerance to a statin becomes an issue, the addition of
nicotinic acid or a fibrate to LDL-C–lowering treatment is
recommended to achieve a non–HDL-C goal no higher than
30 mg/dL above the patient’s LDL-C goal [5].
The choline salt of fenofibric acid formulated as enteric-
coated mini-tablets in a delayed-release capsule (Trilipix,
Abbott, Abbott Park, IL) is indicated for combined use with a
statin to reduce TG and increase HDL-C in CHD or a CHD
risk equivalent patients with mixed dyslipidemia who are on
optimal statin therapy to achieve their LDL-C goal. In three
similarly designed 12-week, controlled clinical studies,
fenofibric acid coadministered with low- or moderate-dose
rosuvastatin, simvastatin, or atorvastatin was found to be
efficacious and well tolerated in patients with mixed dyslipi-
demia [6–8]. A subsequent 52-week, open-label extension of
the three controlled studies evaluated the long-term safety
and efficacy of fenofibric acid coadministered with
moderate-dose statin [9]. This analysis of the extension
study evaluated the long-term efficacy of adding fenofibric
acid 135 mg to moderate-dose statin therapy (rosuvastatin
20 mg, simvastatin 40 mg, or atorvastatin 40 mg) in patients
with LDL-C <100 mg/dL but with TG above 200 mg/dL
after 12 weeks of treatment with moderate-dose statin
monotherapy in the controlled studies.
Methods
This is a post hoc analysis of data collected during a 52-
week open-label extension study of three similarly designed
phase 3, 12-week, multicenter, randomized, controlled,
double-blind studies (NCT00300482, NCT00300469,
NCT00300456). The studies were conducted between
March, 2006 and March, 2008. All patients provided
written informed consent and the studies were approved
by the institutional review board at each center. Eligible
patientsfor the three controlled studies were adults ≥18 years
of age with mixed dyslipidemia defined as screening TG≥
150 mg/dL, LDL-C ≥130 mg/dL, and HDL-C <40 mg/dL
for men and <50 mg/dL for women. Exclusion criteria
included pregnancy, evidence of unstable cardiovascular
disease, type 1 diabetes mellitus, and uncontrolled type 2
diabetes mellitus with hemoglobin A1c >8.5%. Patients who
completed the controlled studies were eligible to enroll in the
open-label extension study.
Details of the study design for the three controlled
studies and the open-label extension study have been
published previously (Fig. 1)[ 6–9]. Each controlled study
used a separate statin (rosuvastatin, simvastatin, or atorvas-
tatin). Briefly, in these controlled studies, after a 6-week
diet run-in/lipid therapy washout period, patients meeting
the eligibility criteria were randomized to 12 weeks of
blinded treatment with fenofibric acid 135 mg; monother-
apy with low- (rosuvastatin 10 mg, simvastatin 20 mg, and
atorvastatin 20 mg), moderate- (rosuvastatin 20 mg, sim-
vastatin 40 mg, and atorvastatin 40 mg), or high-dose
(rosuvastatin 40 mg, simvastatin 80 mg, and atorvastatin
80 mg) statin; or fenofibric acid 135 mg+low- or moderate-
dose statin. The high-dose statin monotherapy groups
enrolled half the number of patients as the other treatment
arms and served as a reference arm for safety in each study.
In the extension study, all patients received fenofibric
acid 135 mg+moderate-dose statin (rosuvastatin 20 mg,
simvastatin 40 mg, or atorvastatin 40 mg) for up to
52 weeks. Patients in the extension study received the
same statin that was used in the controlled study in which
they had participated. At protocol-specified study visits,
patients were evaluated for efficacy and safety measures.
Patient population
The inclusion criteria specified for the present analysis
required patients to: (a) have been treated with moderate-
dose statin monotherapy (rosuvastatin 20 mg, simvastatin
40 mg, or atorvastatin 40 mg) for 12 weeks in one of the
three controlled studies; (b) have entered and received ≥1
dose of treatment with fenofibric acid+moderate-dose statin
in the 52-week open-label extension study; and (c) have
LDL-C <100 mg/dL and TG >200 mg/dL at the start of the
open-label extension study.
Efficacy and safety measures
The efficacy measures for the present analyses were as
follows: (a) percent changes in lipids (non–HDL-C, TG,
LDL-C, and HDL-C) and apolipoprotein (Apo) B levels at
scheduled time points in the 52-week extension study
relative to start of treatment with the combination of
fenofibric acid and moderate-dose statin (hereafter referred
to as baseline); (b) proportion of patients achieving NCEP
ATP III [5] and/or consensus [10] recommended optimal
levels of LDL-C (<100 mg/dL), non–HDL-C (<130 mg/
dL), ApoB (<90 mg/dL), HDL-C (>40 mg/dL in men and
>50 mg/dL in women) and TG (<200 mg/dL and <150 mg/
dL) at baseline, week 12, and final visit of the extension
study; and (c) proportion of patients simultaneously
achieving optimal levels of LDL-C+non–HDL-C, LDL-C
+HDL-C, LDL-C+non–HDL-C+ApoB, and LDL-C+non–
HDL-C+ApoB+HDL-C+TG at baseline, week 12, and
final visit of the extension study. Safety was evaluated
based on data collected for adverse events, physical and
electrocardiographic examinations, vital sign measure-
ments, and clinical laboratory tests. The adverse events
were coded using the Medical Dictionary of Regulatory
60 Cardiovasc Drugs Ther (2011) 25:59–67Activities (MedDRA). Muscle-, hepatic-, and renal-related
adverse events were considered as events of special interest
and were identified utilizing the appropriate standard
MedDRA queries.
Statistical analyses
Mean percent changes from baseline to various time points
were calculated for all efficacy parameters and were
compared using a paired t-test. The number and percentage
of patients attaining optimal individual and combined
targets at week 12 and final visit (week 52 or earlier) were
compared with baseline using McNemar’s test, a nonpara-
metric method used to test for marginal homogeneity of
categorical data with matched pairs of patients and a
dichotomous variable of interest. The test assessed whether
the number/proportion of patients meeting optimal targets
at baseline and after addition of fenofibric acid to moderate-
dose statin therapy were different. The assumptions of
equality do not hold true if the P value is significant, at
which point the proportions indicate the direction of shift.
Baseline was defined as the last value prior to the start of
open-label combination therapy. The last observation
carried forward (LOCF) method was used to impute values
for patients with missing postbaseline values in the
extension study; baseline values were not carried forward.
Results
A total of 2,316 patients completed the three 12-week
controlled studies, of which 364 were treated with
moderate-dose statin monotherapy (rosuvastatin 20 mg,
simvastatin 40 mg, or atorvastatin 40 mg) in the controlled
studies and received at least one dose of fenofibric acid in
combination with moderate-dose statin in the open-label
extension study. Of the 364 patients, 92 (25%) had LDL-C
<100 mg/dL and TG >200 mg/dL at the start of the open-
label extension study. These 92 patients serve as the
subgroup for the present analyses.
Baseline characteristics of the subgroup are summarized
in Table 1. The majority of the patients were white (95%)
and the mean age of the subgroup was 54 years. Based on
the Framingham risk categorization, 41% were considered
as high-risk patients. At the start of the extension study,
mean baseline LDL-C, non–HDL-C, HDL-C, and ApoB
were 78.5 mg/dL, 133.6 mg/dL, 38.8 mg/dL, and 91.5 mg/
dL, respectively; median triglycerides were 249.5 mg/dL
(Table 1).
As shown in Fig. 2, addition of fenofibric acid to
moderate-dose statin for 52 weeks resulted in statistically
significant mean percent reductions in non–HDL-C, ApoB,
and TG at each visit relative to baseline. At final visit, the
mean percent reductions after the addition of fenofibric acid
to moderate-dose statin in non–HDL-C, ApoB, and TG
were 9.0%, 9.8%, and 37.6%, respectively (P<0.001 for all
comparisons). HDL-C and LDL-C levels significantly
increased at each visit relative to baseline; mean percent
increases at final visit in HDL-C and LDL-C were 14.9%
and 12.1%, respectively (P<0.001). Similar changes in
lipid and nonlipid parameters were noted when the data
were analyzed as observed (n=72).
Adding fenofibric acid to moderate-dose statin numeri-
cally increased the proportion of patients with optimal non–
HDL-C (<130 mg/dL) levels from 52.2% at baseline to
63.3% and 64.4% at week 12 and final visit, respectively.
Also, the proportion of patients with optimal ApoB levels
(<90 mg/dL) significantly increased to 61.1% at week 12
and 66.7% at final visit, compared with 40% at baseline
(P≤0.001 for both comparisons). Optimal HDL-C levels of
>40 mg/dL in men and >50 mg/dL in women were
achieved by 33.3% of patients at week 12, and 47.8% of
patients at final visit, compared with 18.9% at baseline (P=
0.02 and P<0.001, respectively). Additionally, the propor-
tion of patients with TG <200 mg/dL was 66.7% and 70%
at week 12 and final visit, respectively, compared with 0%
at baseline (by definition of the population). The median
baseline TG for patients who achieved optimal TG
(<200 mg/dL) was 242 mg/dL (interquartile range: 227–
270 mg/dL), compared with a median baseline TG of
281 mg/dL (interquartile range: 240–557 mg/dL) for those
whose TG was not optimal (≥200 mg/dL). Furthermore, the
proportion of patients with TG <150 mg/dL following
combination treatment was 48.9% at final visit. Finally, the
Controlled Studies
12 weeks
Extension Study
52 weeks
Randomization
Fenofibric Acid Monotherapy
Fenofibric Acid + Low-Dose Statin
Low-Dose Statin Monotherapy
High-Dose Statin Monotherapy
Fenofibric Acid + Moderate-Dose Statin Fenofibric Acid + Moderate-Dose Statin
Moderate-Dose Statin Monotherapy
Open Label
Fig. 1 Design and timeline of
the controlled studies and the
open-label extension study.
Patients with LDL-C <100 mg/
dL but TG >200 mg/dL after
receiving moderate-dose statin
monotherapy in the controlled
studies, who entered and re-
ceived ≥1 dose of treatment with
fenofibric acid+moderate-dose
statin in the 52-week extension
were included in the analysis
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at baseline (by definition of the population) to 78.9% at
final visit (Fig. 3).
The proportion of patients simultaneously achieving
optimal LDL-C+non–HDL-C goals numerically increased
from 52.2% at baseline to 54.4% at week 12 and 60% at final
visit with the addition of fenofibric acid to moderate-dose
statin therapy. The proportion of patients who simultaneously
achieved optimal levels of LDL-C+HDL-C was significantly
higher at final visit than at baseline (38.9% vs 18.9%; P=
0.001). In addition, the proportion of patients simultaneously
achieving optimal LDL-C+non–HDL-C+ApoB targets was
significantly higher at final visit, compared with baseline
(53.3% vs 37.8%; P=0.007). The proportion of patients with
optimal levels of all 5 parameters (LDL-C+non–HDL-C+
ApoB+HDL-C+TG) was also higher at week 12 and final
visit, compared with baseline (14.4% and 25.6% vs 0%)
(Fig. 4). The proportion of patients attaining individual and
combined targets was similar when data were analyzed as
observed (n=72) and the improvements noted at week 12
were sustained through week 52.
The addition of fenofibric acid to moderate-dose statin
therapy was generally well tolerated for 52 weeks. The
most frequently reported adverse events (>5%) were
constipation, gastroenteritis, bronchitis, influenza, naso-
pharyngitis, sinusitis, upper respiratory track infection,
arthralgia, back pain, muscle spasms, dizziness, headache,
cough, and pharyngolaryngeal pain. The incidence of
adverse events and laboratory measurements related to
muscle, hepatic, and renal systems are shown in Table 2.
Over the 52-week treatment period, no rhabdomyolysis was
reported and the incidence of myalgia (4.3%) and myositis
(1.1%) was low. Increases in creatine phosphokinase (CK)
>10x upper limit of normal (ULN) was reported for 1
patient. Alanine aminotransferase (ALT) >3x ULN on 2
consecutive occasions was reported for 1 patient; no
patients had aspartate aminotransferase (AST) >3x ULN
on 2 consecutive occasions.
Characteristic N=92
Gender, n (%)
Women 39 (42.4)
Race, n (%)
White 87 (94.6)
Black 3 (3.3)
Other 2 (2.2)
Ethnicity, n (%)
Hispanic 10 (10.9)
Age, y
Mean (SD) 54.5 (10.93)
≥65, n (%) 16 (17.4)
Tobacco use, n (%)
Tobacco user 26 (28.3)
Former 26 (28.3)
Never 40 (43.5)
Medical history, n (%)
Hypertension 47 (51.1)
Diabetes mellitus type 2 24 (26.1)
Metabolic syndrome
a 69 (75.0)
Coronary artery disease 5 (5.4)
Framingham risk category, n (%)
High 38 (41.3)
Moderate 39 (42.4)
Low 15 (16.3)
Baseline lipids, mg/dL
Low-density lipoprotein cholesterol, mean (SD) 78.5 (13.64)
Non–high-density lipoprotein cholesterol, mean (SD) 133.6 (36.45)
High-density lipoprotein cholesterol, mean (SD) 38.8 (7.31)
Triglycerides, median (min, max) 249.5 (200.9, 2700.0)
Apolipoprotein B, mean (SD) 91.5 (14.19)
Table 1 Baseline characteristics
of the subgroup population
aDetermined according to Nation-
al Cholesterol Education Program
Adult Treatment Panel III defini-
tion [5]
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Fig. 2 Mean percent changes
from baseline in lipid and apoli-
poprotein levels over 52 weeks
after addition of fenofibric acid to
moderate-dose statin therapy.
Baseline was defined as the value
at the end of 12 weeks of
moderate-dose statin monother-
apy in the controlled study, prior
to the start of open-label combi-
nation therapy. Data reported are
based on last observation carried
forward method. P values com-
paring each visit with baseline
wereobtainedfromapairedt-test.
Statistically significant differen-
ces observed at each time point
compared with baseline (week 0)
for non–HDL-C, ApoB, HDL-C,
TG, and LDL-C (P≤0.03 for all
comparisons). At week 16, ApoB
was not measured
Fig. 3 Proportion of patients
with optimal levels of LDL-C
(<100 mg/dL), non–HDL-C
(<130 mg/dL), ApoB (<90 mg/
dL), HDL-C (>40 mg/dL in men
and >50 mg/dL in women), and
TG (<200 mg/dL and <150 mg/
dL) at baseline (after 12 weeks
of treatment with moderate-dose
statin) and at week 12 and final
visit (week 52) after addition of
fenofibric acid to moderate-dose
statin therapy. Data reported are
based on last observation carried
forward method. Statistical
comparisons were not per-
formed for LDL-C and TG
since, by definition, all patients
had optimal levels of LDL-C
and no patients had optimal
levels of TG at baseline
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This post hoc analysis of a 52-week safety and efficacy
study of fenofibric acid in combination with moderate-dose
statin demonstrated that in patients who were at goal for
LDL-C (<100 mg/dL), but had persistent elevated TG
(>200 mg/dL) after 12 weeks of treatment with a moderate
dose-statin, the long-term addition of fenofibric acid
resulted in significant improvements in non–HDL-C,
ApoB, HDL-C, and TG. In addition, the proportion of
patients achieving optimal levels of non–HDL-C, ApoB,
HDL-C, and TG, as well as combined targets of these
variables and LDL-C increased from baseline to final visit
with the addition of fenofibric acid to moderate-dose statin.
The NCEPATP III guidelines recognize elevated TG as a
marker of atherogenic remnant lipoproteins and increased
cardiovascular risk [5]. The ATP III recommends non–HDL-
C, a measure of the cholesterol content in LDL,
intermediate-density lipoprotein (IDL), and very–low-density
lipoprotein (VLDL) as a secondary treatment target (after
LDL-C) in patients with TG ≥200 mg/dL. Along with LDL-
C and non–HDL-C, the American Diabetes Association/
American College of Cardiology Foundation consensus
report has recommended ApoB as both a marker for CHD
risk and a target in patients with cardiometabolic risk, whose
typical lipoprotein profile includes high TGs and/or low
HDL-C [10]. The patients in this analysis, at goal for LDL-C
but with elevated TGs despite treatment with moderate-dose
statin monotherapy, qualify for the addition of a niacin or a
fibrate based on treatment guidelines. As such, both non–
HDL-C and ApoB levels were improved from baseline to
week 12 and were sustained until week 52 with the addition
Fig. 4 Proportion of patients simultaneously achieving optimal levels
for multiple parameters (LDL-C+non–HDL-C; LDL-C+HDL-C,
LDL-C+non–HDL-C+ApoB, and LDL-C+non–HDL-C+ApoB+
HDL-C+TG) at baseline (after 12 weeks of treatment with
moderate-dose statin) and at week 12 and final visit (week 52) after
addition of fenofibric acid to moderate-dose statin therapy. The
optimal levels for each parameter were LDL-C <100 mg/dL, non–
HDL-C <130 mg/dL, HDL-C >40 mg/dL for men and >50 mg/dL for
women, ApoB <90 mg/dL, and TG <150 mg/dL. Data reported are
based on last observation carried forward method. Statistical compar-
isons were not performed for the achievement of optimal levels of the
five parameters (LDL-C+non–HDL-C+ApoB+HDL-C+TG) since,
by definition, no patients had optimal levels of TG at baseline
Incidence, n (%)
N=92
Hepatic
ALT >5x ULN 0 (0.0)
ALT >3x ULN on 2 consecutive occasions 1 (1.1)
AST >5x ULN 0 (0.0)
AST >3x ULN on 2 consecutive occasions 0 (0.0)
Muscle
CK >5x ULN 2 (2.2)
CK >10x ULN 1 (1.1)
Myalgia 4 (4.3)
Myositis 1 (1.1)
Rhabdomyolysis 0 (0.0)
Renal
Creatinine >2 mg/dL 1 (1.1)
Creatinine ≥50% increase from baseline and >1x 6 (6.6)
ULN on a single occasion
Creatinine ≥100% increase from baseline 1 (1.1)
Table 2 Incidence of adverse
events and laboratory measure-
ments
ALT alanine aminotransferase,
AST aspartate aminotransferase,
CK creatine phosphokinase,
ULN upper limit of normal
64 Cardiovasc Drugs Ther (2011) 25:59–67of fenofibric acid to moderate-dose statin therapy. Further-
more, median TG levels decreased to near 150 mg/dL at
final visit and mean HDL-C levels significantly increased to
>40 mg/dL at final visit in this subgroup of patients.
In this analysis, the mean baseline LDL-C at the start of
the extension study was 79 mg/dL. After the addition of
fenofibric acid to moderate-dose statin therapy, mean LDL-
C increased to 87 mg/dL resulting in 21.1% of patients no
longer having LDL-C <100 mg/dL at the final visit.
However, the percentage of patients with optimal non–
HDL-C levels (<130 mg/dL) increased by 12% and those
with optimal ApoB levels (<90 mg/dL) increased by 27% at
final visit. These results suggest that the net effect of adding
fenofibric acid to moderate-dose statin therapy is an
increase in LDL particle size (as measured by the increase
in cholesterol content in the LDL fraction) and a reduction
in atherogenic particle number as measured by ApoB. The
increase in LDL-C noted in this subgroup of patients with
hypertriglyceridemia is not unexpected, as baseline TGs
have been shown to influence the LDL-C–lowering effect
of statin+fibrate combinations (greater reductions with low
baseline TGs) [11]. In patients with high TG, treatment
with fibrates results in an increase in measured LDL-C
content, likely because of fibrate-induced increased lipoly-
sis of TG-rich VLDL particles [12, 13] and/or a shift in
LDL particle size [14–17]. Despite the benefits in LDL
particle size and number, and improvements in other lipid
parameters, a patient’s CHD risk should be considered
when making treatment decisions for patients whose LDL-
C is >100 mg/dL. The primary aim of treatment, according
to NCEP ATP III guidelines, is to achieve LDL-C goal
(<100 mg/dL for high-risk patients, <130 mg/dL for
moderate-risk patients, and <160 mg/dL for low-risk
patients). Combination therapy may be considered to treat
the secondary non–HDL-C goal in patients with TG ≥
200 mg/dL only after the LDL-C goal has been reached.
Inthe present study, the proportionofpatientswithoptimal
HDL-C increased by 29%, and 70% of the patients had TG
<200 mg/dL by final visit. A sar e s u l t ,ah i g h e rp e r c e n t a g eo f
patients had optimal levels of multiple parameters such as
LDL-C+non–HDL-C, LDL-C+HDL-C, LDL-C+non–
HDL-C+ApoB, and LDL-C+non–HDL-C+ApoB+HDL-C
+TG with the addition of fenofibric acid to moderate-dose
statin for 52 weeks. As TG levels at final visit remained
≥200 mg/dL in 30% of the patients, we compared the
baseline TG values of patients who achieved optimal TG
versus those whose TG was not optimal. Patients whose TG
remained at or above the threshold at final visit started with
much higher baseline TG values (median 281 mg/dL) than
those whose TG dropped below the threshold (median
242 mg/dL). Although statin monotherapy is known to
reduce TG levels, the final median TG of 152.0 mg/dL in our
study represents a substantial reduction in TG from a
baseline median of 249.5 mg/dL with the addition of
fenofibric acid to moderate-dose statin therapy.
Other treatment strategies for normalizing multiple lipid
parameters in patients with mixed dyslipidemia include the
addition of nicotinic acid or omega 3-fatty acids to statin
therapy. Both strategies have been evaluated in long-term
safety and efficacy studies and have resulted in improve-
ments of lipid parameters other than LDL-C [18, 19].
Addition of omega-3 fatty acids (as eicosapentaenoic acid)
to statin therapy has been shown in one study to
significantly reduce major coronary events in patients with
hypercholesterolemia although the study did not require
elevated TG for patients to enroll [19], while outcomes
studies are ongoing to demonstrate the incremental benefit
of adding niacin to statin treatment. It should be noted that
although the combination of fenofibrate and simvastatin in
the Action to Control Cardiovascular Risk in Diabetes
(ACCORD) study did not significantly reduce the rate of
nonfatal myocardial infarction, nonfatal stroke, or cardio-
vascular death compared with simvastatin alone, a prespe-
cified analysis demonstrated a 31% relative risk reduction
in cardiovascular events in patients with both high TG
(≥204 mg/dL) and low HDL-C (≤34 mg/dL) compared to
treatment with statin alone [20]. The data from ACCORD
are consistent with other fibrate trials showing that a subset
of patients with elevated TGs and low HDL-C have
cardiovascular benefit [21–23].
As mentioned earlier, guidelines recommend non–HDL-
C and ApoB as additional secondary targets in patients with
TG ≥200 mg/dL [5, 10, 24–26]. The NEPTUNE II study, a
national survey estimating goal attainment with statin
therapy, found that achievement of the combined LDL-C
+non–HDL-C targets among patients with TG ≥200 mg/dL
ranged from 78% in the low-risk category to 27% in the
high-risk category [27]. In a separate post hoc study of
metabolic syndrome patients, the combined target of LDL-
C+non–HDL-C was achieved by 67% of patients after
6 weeks of treatment with rosuvastatin 40 mg [28]. The
current analysis suggests that combination therapy with
fenofibric acid+moderate-dose statin may offer a strategy
to improve these goal attainment observations.
Bays et al. have previously reported the safety findings
for the overall population of the open-label extension study
[9]. The addition of fenofibric acid to moderate-dose statin
for 52 weeks in the current analysis was well tolerated. The
incidence of myalgia and myositis was low; no rhabdo-
myolysis was reported. Elevations in liver enzymes were
rare in this subgroup. Incidence of CK elevations was low,
as were elevations in creatinine. Similar to the overall
population, no new or unexpected adverse events were
observed with 52-week exposure to fenofibric acid in
combination with moderate-dose statin in the present
analysis.
Cardiovasc Drugs Ther (2011) 25:59–67 65The primary limitations of this study are the open-label
nature of the extension study, the post hoc nature of the
analysis, and small size (N=92) of the subgroup. Other
limitations of the study are that all patients were treated
with combination therapy and no comparisons with placebo
or individual monotherapies were made. Additionally,
although this analysis evaluated the effects of adding
fenofibric acid to moderate-dose statin therapy on several
lipid and apolipoprotein parameters, only reductions in
LDL-C has been correlated with favorable cardiovascular
outcomes.
Conclusions
In conclusion, this analysis evaluating the efficacy and
safety of adding fenofibric acid to moderate-dose statin
therapy over 52 weeks in a subgroup of patients with LDL-
C<100 mg/dL and TG >200 mg/dL showed that the
secondary treatment target of non–HDL-C, along with
ApoB, TG, and HDL-C were all improved with combina-
tion therapy compared with statin monotherapy with an
acceptable safety profile.
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